91 related articles for article (PubMed ID: 25964530)
1. Uniform Combretastatin-induced Effect on Monocytes and Neutrophils in Peripheral Blood but Not in Tumors.
Bohn AB; Brems-Eskildsen AS; Møller BK; Horsman MR
Anticancer Res; 2015 May; 35(5):2559-64. PubMed ID: 25964530
[TBL] [Abstract][Full Text] [Related]
2. A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models.
Bohn AB; Wittenborn T; Brems-Eskildsen AS; Laurberg T; Bertelsen LB; Nielsen T; Stødkilde-Jørgensen H; Møller BK; Horsman MR
PLoS One; 2014; 9(10):e110091. PubMed ID: 25299269
[TBL] [Abstract][Full Text] [Related]
3. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
5. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo.
Yao N; Ren K; Jiang C; Gao M; Huang D; Lu X; Lou B; Peng F; Yang A; Wang X; Ni Y; Zhang J
Tumour Biol; 2015 Nov; 36(11):8499-510. PubMed ID: 26026583
[TBL] [Abstract][Full Text] [Related]
6. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.
Malcontenti-Wilson C; Muralidharan V; Skinner S; Christophi C; Sherris D; O'Brien PE
Clin Cancer Res; 2001 Apr; 7(4):1052-60. PubMed ID: 11309357
[TBL] [Abstract][Full Text] [Related]
7. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
8. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
9. A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
Abma E; De Spiegelaere W; Vanderperren K; Stock E; Van Brantegem L; Cornelis I; Daminet S; Ni Y; Vynck M; Verstraete G; Smets P; de Rooster H
Vet Comp Oncol; 2018 Dec; 16(4):467-477. PubMed ID: 29797763
[TBL] [Abstract][Full Text] [Related]
10. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A4 phosphate: a novel vascular disrupting agent.
Nagaiah G; Remick SC
Future Oncol; 2010 Aug; 6(8):1219-28. PubMed ID: 20799867
[TBL] [Abstract][Full Text] [Related]
12. Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
Horsman MR; Wittenborn TR; Nielsen PS; Elming PB
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640548
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy.
Nabha SM; Mohammad RM; Wall NR; Dutcher JA; Salkini BM; Pettit GR; Al-Katib AM
Anticancer Drugs; 2001 Jan; 12(1):57-63. PubMed ID: 11272287
[TBL] [Abstract][Full Text] [Related]
14. Characterizing the tumor response to treatment with combretastatin A4 phosphate.
Salmon BA; Siemann DW
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):211-7. PubMed ID: 17448875
[TBL] [Abstract][Full Text] [Related]
15. Enhancing the radiation response of tumors but not early or late responding normal tissues using a vascular disrupting agent.
Horsman MR
Acta Oncol; 2017 Nov; 56(11):1634-1638. PubMed ID: 28838284
[TBL] [Abstract][Full Text] [Related]
16. Combretastatin-induced hypertension and the consequences for its combination with other therapies.
Busk M; Bohn AB; Skals M; Wang T; Horsman MR
Vascul Pharmacol; 2011; 54(1-2):13-7. PubMed ID: 21040805
[TBL] [Abstract][Full Text] [Related]
17. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Salmon HW; Siemann DW
Clin Cancer Res; 2006 Jul; 12(13):4090-4. PubMed ID: 16818709
[TBL] [Abstract][Full Text] [Related]
18. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
Lunt SJ; Akerman S; Hill SA; Fisher M; Wright VJ; Reyes-Aldasoro CC; Tozer GM; Kanthou C
Int J Cancer; 2011 Oct; 129(8):1979-89. PubMed ID: 21154772
[TBL] [Abstract][Full Text] [Related]
19. Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.
Thomas CD; Walczak C; Kaffy J; Pontikis R; Jouanneau J; Volk A
Neoplasia; 2006 Jul; 8(7):587-95. PubMed ID: 16867221
[TBL] [Abstract][Full Text] [Related]
20. Comparison of two vascular-disrupting agents at a clinically relevant dose in rodent liver tumors with multiparametric magnetic resonance imaging biomarkers.
Wang H; Cona MM; Chen F; Yu J; Feng Y; Li J; Keyzer FD; Marchal G; Ni Y
Anticancer Drugs; 2012 Jan; 23(1):12-21. PubMed ID: 21857503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
